Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Naproxen 500 Mg Clear all

Conditions: Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions: Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Migraine, Tension-type Headache, Primary Headache Disorder
Interventions: Sumatriptan 100 mg, Naproxen; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Healthy
Interventions: LT-NS001, Naprosyn®; Drug
Lead sponsor: Logical Therapeutics; Industry
Eligibility: 45 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), PN 400 (VIMOVO); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pharmacokinetics
Interventions: Naproxen Sodium, (BAY H6689), Naprelan, (BAY H6689); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Osteoarthritis, Knee
Interventions: Naproxen, Placebo; Drug
Lead sponsor: Analgesic Solutions; Industry
Eligibility: 21 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Natick, Massachusetts

Conditions: Anterior Cruciate Ligament Rupture
Interventions: Oxycodone, Placebo oral tablet; Drug
Lead sponsor: Emory University; Other
Eligibility: 14 Years to 40 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Atlanta, Georgia • Tucker, Georgia

Conditions: Osteo Arthritis Knee
Interventions: V120083, Naproxen, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 30
States / cities: Birmingham, Alabama • Tuscumbia, Alabama • North Hollywood, California + 24 more

Conditions: Osteoarthritis Pain of the Knee
Interventions: VM902A 200-mg Capsules, VM902A 400-mg Capsules, Naproxen 500-mg Capsules, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 31
States / cities: Birmingham, Alabama • Huntsville, Alabama • DeLand, Florida + 28 more

Conditions: Gout
Interventions: Allopurinol, Naproxen 250 MG, Colchicine 0.6 mg, Colchicine 1.2 mg, Naproxen 500 Mg, Prednisone 40 mg; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: South Birmingham, Alabama • Santa Monica, California • Boston, Massachusetts + 2 more

Conditions: Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
Interventions: Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2050
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Opioid Use, Spinal Diseases, Surgery--Complications, Surgery, Postoperative Pain
Interventions: Opioid Analgesic, Opioid-Free Postoperative Pain Regimen; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Gout, Hyperuricemia
Interventions: Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pain, Postoperative, ACL
Interventions: OxyCODONE 5 mg Oral Tablet, Naproxen 500 Mg, Tylenol Pill, Liposomal bupivacaine, Femoral Nerve Catheter; Drug · Procedure
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anterior Cruciate Ligament Reconstruction
Interventions: Ropivacaine 0.5%, Percocet 7.5/325, Naprosyn 500 mg; Drug
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions: PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: Dental Pain
Interventions: Naproxen Test, Naprosyn, Placebo; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 254 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Osteoarthritis
Interventions: PH-797804, Placebo, Naproxen, Naproxen + PH-797804; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 26
States / cities: Paramount, California • Spring Valley, California • Valley Village, California + 20 more

Conditions: Osteoarthritis
Interventions: Naproxen, flavocoxid 250 mg, flavocoxid 500 mg; Drug · Dietary Supplement
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid Consumption
Interventions: Naproxen, Acetaminophen, oxycodone, Gabapentin; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Volunteers
Interventions: Naproxen, PL 3100; Drug
Lead sponsor: PLx Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis
Interventions: PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid; Drug
Lead sponsor: POZEN; Industry
Eligibility: 50 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Arthritis, Rheumatoid
Interventions: celecoxib, Ibuprofen, Naproxen; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 871
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 515 more

Conditions: Osteoarthritis
Interventions: PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid; Drug · Other
Lead sponsor: POZEN; Industry
Eligibility: 50 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

Comparing Naproxen to Sumatriptan for Emergency Headache Patients

Comparator Study of LT-NS001 in Healthy Subjects With Endoscopic Evaluation

A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)

Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan

Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee

Are Opioids Needed After ACL Reconstruction

A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee

A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

CHronic Nonbacterial Osteomyelitis International Registry

Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

Post Operative Pain Management Through Adductor Canal Block With Bupivacaine for ACL Reconstruction

Anterior Cruciate Ligament Pain Study

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Study of Naproxen Capsules to Treat Dental Pain

Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee

Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity

Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis